VYXARIQ Trademark

Trademark Overview

On Wednesday, December 30, 2020, a trademark application was filed for VYXARIQ with the United States Patent and Trademark Office. The USPTO has given the VYXARIQ trademark a serial number of 90430299. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, November 11, 2024. This trademark is owned by Applied Therapeutics, Inc.. The VYXARIQ trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for treatment of diabetes complications; Pharmaceutical preparations for treatment of heart diseases or disorders, eye diseases or disorders, nervous system diseases or disorders, kidney diseases or disorders, cardiomyopathy, neuropathy, retinopathy, and nephropathy; Pharmaceutical preparations for inhibiting aldose reductase
vyxariq

General Information

Serial Number90430299
Word MarkVYXARIQ
Filing DateWednesday, December 30, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, November 11, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 10, 2021

Trademark Statements

Goods and ServicesPharmaceutical preparations for treatment of diabetes complications; Pharmaceutical preparations for treatment of heart diseases or disorders, eye diseases or disorders, nervous system diseases or disorders, kidney diseases or disorders, cardiomyopathy, neuropathy, retinopathy, and nephropathy; Pharmaceutical preparations for inhibiting aldose reductase

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, March 24, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameApplied Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
Party NameApplied Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10173

Trademark Events

Event DateEvent Description
Sunday, January 31, 2021TEAS CHANGE OF OWNER ADDRESS RECEIVED
Sunday, January 31, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sunday, January 31, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sunday, January 31, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sunday, January 31, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, July 1, 2021ASSIGNED TO EXAMINER
Tuesday, July 6, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, January 2, 2021NEW APPLICATION ENTERED
Wednesday, March 24, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, July 21, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 10, 2021PUBLISHED FOR OPPOSITION
Tuesday, August 10, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 5, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 22, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, March 22, 2022SOU EXTENSION 1 FILED
Tuesday, March 22, 2022SOU EXTENSION 1 GRANTED
Thursday, March 24, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, September 9, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 12, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, September 12, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, September 12, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, March 10, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, September 7, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, September 7, 2022SOU EXTENSION 2 FILED
Wednesday, September 7, 2022SOU EXTENSION 2 GRANTED
Friday, March 10, 2023SOU EXTENSION 3 FILED
Friday, March 10, 2023SOU EXTENSION 3 GRANTED
Tuesday, September 19, 2023SOU TEAS EXTENSION RECEIVED
Thursday, September 21, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 22, 2024SOU TEAS EXTENSION RECEIVED
Friday, March 22, 2024SOU EXTENSION 5 FILED
Tuesday, March 14, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 19, 2023SOU EXTENSION 4 FILED
Tuesday, September 19, 2023SOU EXTENSION 4 GRANTED
Friday, March 22, 2024SOU EXTENSION 5 GRANTED
Monday, November 11, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, November 11, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Saturday, March 23, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

vyxariq diseases disorders preparations pharmaceutical treatment retinopathy nephropathy inhibiting reductase aldose